Clinical Trial Update: GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for GQ1001 combined with Pyrotinib in HER2-positive metastatic breast cancer across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GQ1001
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: Advanced/ Metastatic Her-2 Positive Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN